skip to main content
Global Search Configuration

We’re excited to share our latest report on gene, cell, and rna therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q3 2022 report calls out important updates and changes within the gene, cell, and rna therapy landscape. 

Highlights of the report include:

  • Multiple first approvals for gene and rna therapies
    • Zynteglo and Skysona were also approved in the U.S., but not considered as new approvals as both therapies were previously approved in and subsequently withdrawn from the E.U.
  • The non-genetically modified cell therapy pipeline has remained consistent with the previous quarter
    • Overall, pipeline development is focused mostly on anticancer indications, followed by rare diseases
    • Within rare diseases, development is dominated by non-oncology indications, representing 63% of rare disease development for this therapy type
  • Companies obtaining start-up funding continue to increase
    • 19 companies brought in seed or Series A financing, up from 17 in Q2 2022.
    • Capstan Therapeutics raised $102 million in its Series A round to support work on mRNA-encoded CARs and mRNA-encoded gene editing
    • Dealmaking for advanced molecular therapy companies saw an increase from Q2

Report Contributors

Practice Lead

Ly Nguyen-Jatkoe, PhD

Executive Director, Pharma Custom Intelligence

Ly Specialises in

  • Competitive Intelligence
  • Business Development and Licensing
  • Product Launch and Commercial Strategy

22+ years of experience


Amanda Micklus

Senior Pharma Consultant

Connecticut , USA

Amanda Micklus_Pharma_Intelligence

Amanda Specialises in

  • Business Development and Licensing
  • Market intelligence
  • Primary market research

23+ years of experience


Shardha Millington

Consultant, Pharma Custom Intelligence
Shardha Millington

Shardha Specialises in

  • Market intelligence
  • Drug development
  • Research and Development
  • Competitive Intelligence

Previous Reports

Thank you for requesting a demo

We have received your request and we will get back to you soon.

By continuing, you accept Pharma Intelligence UK may contact you with updates, relevant promotions and information about products provided by Pharma Intelligence UK. You understand that your information will be used in accordance with our Privacy Policy, and that you may withdraw your permission to receive any of our communications at any time.

You can unsubscribe at any time by following the links in any emails we send to you or by emailing See our Privacy Policy.